Eversept Partners LP Acquires Shares of 231,380 Xenon Pharmaceuticals Inc. $XENE

Eversept Partners LP acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 231,380 shares of the biopharmaceutical company’s stock, valued at approximately $10,370,000. Eversept Partners LP owned about 0.30% of Xenon Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Cinctive Capital Management LP lifted its holdings in Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after purchasing an additional 263 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Xenon Pharmaceuticals by 7.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after purchasing an additional 14,871 shares during the last quarter. Abel Hall LLC purchased a new stake in Xenon Pharmaceuticals during the fourth quarter valued at about $303,000. Lazard Asset Management LLC purchased a new stake in Xenon Pharmaceuticals during the fourth quarter valued at about $3,526,000. Finally, Amundi purchased a new stake in Xenon Pharmaceuticals during the fourth quarter valued at about $207,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Up 2.3%

Shares of XENE opened at $53.20 on Thursday. The business’s 50-day moving average price is $55.16 and its 200-day moving average price is $49.17. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $63.95. The stock has a market cap of $5.14 billion, a PE ratio of -11.32 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting the consensus estimate of ($1.17). During the same period in the prior year, the firm earned ($0.83) EPS. Analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on XENE shares. Deutsche Bank Aktiengesellschaft upped their price target on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Guggenheim reiterated a “buy” rating and set a $90.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Jefferies Financial Group set a $100.00 price target on Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Robert W. Baird upped their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $77.20.

Insider Activity at Xenon Pharmaceuticals

In related news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.07% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.